🇺🇸 FDA
Patent

US 10596216

Use of a Withania extract for the treatment of amyloid-related diseases

granted A61KA61K2236/19A61K2236/39

Quick answer

US patent 10596216 (Use of a Withania extract for the treatment of amyloid-related diseases) held by Ethnodyne and Centre National de la Recherche Scientifique (CNRS) expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ethnodyne and Centre National de la Recherche Scientifique (CNRS)
Grant date
Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2236/19, A61K2236/39, A61K36/068, A61K36/185